|Opportunity Name||Cancer Therapeutics Innovation Pipeline (CTIP) Program|
|Agency||Ontario Institute for Cancer Research (OICR)|
|Value||Early Validation projects – Up to $150,000/year|
Early Accelerator projects – Up to $150,000
Late Accelerator project – Up to $500,000/year
|Indirect Costs||Eligible at 30%|
|Duration||Early Validation projects – Up to 2 years|
Early Accelerator projects – Up to 1 year
Late Accelerator project – Up to 2 years
Letter of Intent (LOI)
Note: The deadline for submission of the Notice of Intent (NOI) is the same as the deadline for Letter of Intent (LOI) submission, however, applicants are encouraged to submit their NOI as early as possible to assist with planning and to ensure sufficient time to complete the LOI by the deadline.
|Notice of Intent (NOI) due at agency||05-03-2023, by 5:00PM|
|LOI due to FSc RO at email@example.com for full review||04-19-2023|
|LOI and fully signed ORS checklist due to FSc RO at firstname.lastname@example.org for mandatory review||04-26-2023|
|LOI and fully signed ORS checklist due at ORS for mandatory review||05-01-2023, by 9:00AM|
|LOI due at agency||05-03-2023, by 5:00PM|
Full application (by invitation only)
|Application due to FSc RO at email@example.com for full review||07-19-2023|
|Application and fully signed ORS checklist due to FSc RO at firstname.lastname@example.org for mandatory review||07-26-2023|
|Final application and fully signed ORS checklist due at ORS for mandatory review||07-31-2023, by 9:00AM|
|Application due at agency||08-02-2023, by 5:00PM|
- To create a pipeline of validated cancer targets and first-in-class or best-in-class, novel, selective lead molecules (small molecules or biologics) that will attract partnerships and/or investment for further preclinical and clinical development; and
- Support projects that aim to provide increasing evidence of target validation and disease association using data from knowledge bases, functional assays, and drug screening in relevant in vitro and in vivo models of the cancer type of interest.
CTIP funds projects in four stages of preclinical drug discovery and is currently inviting applications for the following three funding streams:
Early Validation projects: Deliver robust translational evidence that a Target-of-Interest (TOI) is associated with a specific cancer type based on data from knowledge bases and from studies demonstrating that perturbation of the TOI in relevant cell-based or higher models produces anti-cancer effects sufficient to trigger a drug discovery campaign.
Early Accelerator projects: Deliver a validated primary assay to enable initial screening of molecules against a defined target. Preliminary evidence of linearity of results between the primary assay and supporting secondary assays under development is also required.
Late Accelerator projects: Deliver confirmed Hit molecules against a defined target using validated primary, secondary and orthogonal assays for screening.
OICR invites applications from investigators at Ontario academic centres, hospital research institutes, or other government research institutions. CTIP funding is only tenable in Ontario. For-profit entities are not eligible to apply.
An information session will be held on Tuesday, April 18, 2023 from 2:00–3:00 PM EST.
How to Apply
York University researchers are reminded that all applications for external research funding, including Letters of Intent, must be reviewed and approved by the Office of Research Services before they are submitted to the granting agency. For internal approval, the application must be accompanied by a completed ORS Checklist, which requires the Dean’s signature. Please send the complete application, with the finalized budget and a completed ORS checklist to email@example.com, five days prior to agency deadline.
ORS is accepting electronic applications – the process is outlined here.